Search

Abstract Breast cancer is the most common cancer among women, with over 1 million new cases and around 400,000 deaths annually worldwide. This makes it a significant and costly global health challenge. Standard treatments like chemotherapy and radiotherapy, often used after mastectomy, show varying effectiveness based on the cancer subtype. Combining these treatments can improve outcomes, though radiotherapy faces limitations such as radiation resistance and low selectivity for malignant cells. Nanotechnologies, especially metallic nanoparticles (NPs), hold promise for enhancing radiotherapy. Gold nanoparticles (AuNPs) are particularly notable due to their high atomic number, which enhances radiation damage through the photoelectric effect. Studies shown that AuNPs can act as effective radiosensitizers, improving tumor damage during radiotherapy increasing the local radiation dose delivered. Traditional AuNPs synthesis methods involve harmful chemicals and extreme conditions, posing health risks. Green synthesis methods using plant extracts offer a safer and more environmentally friendly alternative. This study investigates the synthesis of AuNPs using Laurus nobilis leaf extract and their potential as radiosensitizers in breast carcinoma cell lines (MCF-7). These cells were exposed to varying doses of X-ray irradiation, and the study assessed cell viability, morphological changes and DNA damage. The results showed that green-synthesized AuNPs significantly enhanced the therapeutic effects of radiotherapy at lower radiation doses, indicating their potential as a valuable addition to breast cancer treatment.

Abstract: CD37-directed antibody and cellular-based approaches have shown preclinical and promising early clinical activity. Naratuximab emtansine (Debio 1562; IMGN529) is an antibody-drug conjugate (ADC) incorporating an anti-CD37 monoclonal antibody conjugated to the maytansinoid DM1 as payload, with activity as a single agent and in combination with rituximab in patients with lymphoma. We studied naratuximab emtansine and its free payload in 54 lymphoma models, correlated its activity with CD37 expression, characterized two resistance mechanisms, and identified combination partners providing synergy. The activity, primarily cytotoxic, was more potent in B- than T-cell lymphoma cell lines. After prolonged exposure to the ADC, one diffuse large B-cell lymphoma (DLBCL) cell line developed resistance to the ADC due to the CD37 gene biallelic loss. After CD37 loss, we also observed upregulation of interleukin-6 (IL-6) and related transcripts. Recombinant IL-6 led to resistance. Anti-IL-6 antibody tocilizumab improved the ADC’s cytotoxic activity in CD37+ cells. In a second model, resistance was sustained by a PIK3CD activating mutation, with increased sensitivity to PI3Kδ inhibition and a functional dependence switch from MCL1 to BCL2. Adding idelalisib or venetoclax overcame resistance in the resistant derivative and improved cytotoxic activity in the parental cells. In conclusion, targeting B-cell lymphoma with the naratuximab emtansine showed vigorous antitumor activity as a single agent, which was also observed in models bearing genetic lesions associated with inferior outcomes, such as Myc Proto-Oncogene (MYC) translocations and TP53 inactivation or R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) resistance. Resistant DLBCL models identified active combinations of naratuximab emtansine with drugs targeting IL-6, PI3Kδ, and BCL2.

In recent years, the scientific community’s interest in nanoscience and nanotechnology stems from the increasing capability to manipulate matter at the nanoscale. Nanotechnology development is closely linked to fabricating and characterizing structures below 100 nm, driven by technological advancements enabling their in-depth analysis. Up to now, several top-down and bottom-up nanofabrication approaches have been developed to realize a plethora of nanostructures. Although effective, these methods have many drawbacks like high costs and limitations in feature size. In this scenario, Scanning Probe-based Lithography (SPL) emerges as a very promising alternative to conventional nanofabrication techniques, overcoming their main method limitations with versatility, flexibility, low cost, and nanoscale resolution. This review focuses on mechanical Scanning Probe-based Lithography (m-SPL), tracing its evolution from inception to recent advances. Different m-SPL methods, such as Nanoindentation, Static and Dynamic Plowing lithography, Nanomilling, and their variants are discussed in-depth, emphasizing their advantages and drawbacks, and highlighting their application. Moreover, this review explores the effects of combining m-SPL with other energy sources, such as heat and electric energy, and outlines future perspectives in the field. Overall, m-SPL stands out as a promising avenue in nanofabrication, offering sub-nanometer resolution and diverse material manipulation capabilities.

Hematological cancers are among the most common cancers in adults and children. Despite significant improvements in therapies, many patients still succumb to the disease. Therefore, novel therapies are needed. The Wiskott-Aldrich syndrome protein (WASp) family regulates actin assembly in conjunction with the Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively in hematopoietic cells and exists in two allosteric conformations: autoinhibited or activated. Here, we describe the development of EG-011, a first-in-class small molecule activator of the WASp auto-inhibited form. EG-011 possesses in vitro and in vivo anti-tumor activity as a single agent in lymphoma, leukemia, and multiple myeloma, including models of secondary resistance to PI3K, BTK, and proteasome inhibitors. The in vitro activity was confirmed in a lymphoma xenograft. Actin polymerization and WASp binding was demonstrated using multiple techniques. Transcriptome analysis highlighted homology with drugs-inducing actin polymerization.

Antibody-drug conjugates (ADCs) represent one of the most successful therapeutic approaches introduced in clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19 targeting ADC, in which the antibody is conjugated through a protease cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer warhead (SG3199). Based on the results of a phase 2 study, loncastuximab tesirine was recently approved for adult patients with relapsed/refractory large B-cell lymphoma. We assessed the activity of loncastuximab tesirine using in vitro and in vivo models of lymphomas, correlated its activity with CD19 expression levels, and identified combination partners providing synergy with loncastuximab tesirine. Loncastuximab tesirine was tested across 60 lymphoma cell lines. Loncastuximab tesirine had strong cytotoxic activity in B-cell lymphoma cell lines. The in vitro activity was correlated with CD19 expression level and intrinsic sensitivity of cell lines to the ADC’s warhead. Loncastuximab tesirine was more potent than other anti-CD19 ADCs (coltuximab ravtansine, huB4-DGN462), albeit the pattern of activity across cell lines was correlated. Loncastuximab tesirine activity was also largely correlated with cell line sensitivity to R-CHOP. Combinatorial in vitro and in vivo experiments identified the benefit of adding loncastuximab tesirine to other agents, especially BCL2 and PI3K inhibitors. Our data support the further development of loncastuximab tesirine as a single agent and in combination for patients affected by mature B-cell neoplasms. The results also highlight the importance of CD19 expression and the existence of lymphoma populations characterized by resistance to multiple therapies.

Abstract Neurodegenerative diseases (NDs) impose substantial medical and public health burdens on people worldwide and represent one of the major threats to human health. The prevalence of these age‐dependent disorders is dramatically increasing over time, a process intrinsically related to a constantly rising percentage of the elderly population in recent years. Among all the NDs, Alzheimer's and Parkinson's are considered the most debilitating as they cause memory and cognitive loss, as well as severely affecting basic physiological conditions such as the ability to move, speak, and breathe. There is an extreme need for new and more effective therapies to counteract these devastating diseases, as the available treatments are only able to slow down the pathogenic process without really stopping or resolving it. This review aims to elucidate the current nanotechnology‐based tools representing a future hope for NDs treatment. Noble metal nano‐systems, that is, gold and silver nanoparticles (NPs), have indeed unique physicochemical characteristics enabling them to deliver any pharmacological treatment in a more effective way within the central nervous system. This can potentially make NPs a new hope for reversing the actual therapeutic strategy based on slowing down an irreversible process into a more effective and permanent treatment.

In recent times, the searches for alternative materials to plastic is a popular topic, due to the danger that synthetic materials cause to the environment and humans. Among the promising natural polymers, chitosan (CS) is certainly one of the most suitable since it it is edible, non-toxic and derives from crustacean waste.- However, it is necessary to improve its physical properties to be widely applied in food packaging, whose market is dominated by synthetic plastic. In this work we have synthesized silver nanoparticles (AgNPs) using hot-plate and microwaves-based techniques, using Aloe Vera leaves extracts. The synthetic process follows the principles of green chemistry, since no toxic substance is used to obtain nanomaterials. These NPs, having dimensions

Traditional life cycle assessment (LCA) is too data intensive and time consuming to be used during typical building design processes. Conducting an LCA during the building design process therefore requires simplifications and assumptions. Such “screening LCAs” are quicker and can be used with less data but introduce greater uncertainty. Unfortunately, uncertainty is not reflected in standard deterministic LCA calculations, which produce single-point values in LCA results. Thus, in this study, data quality scoring has been incorporated into a screening LCA to produce probabilistic predictions of environmental performance based on limited data. The approach has been applied during the design process of a bio-based wall panel designed for a circular economy. A combination of ecoinvent and material data sheets were used to analyse a wide range of novel bio-based insulation materials. The screening LCA analysed global warming potential and identified a short-list of promising materials that were then subjected to a detailed LCA for further consideration in the design. The method uses publicly available information and can be applied at material or building-element level. The method thus helps designers estimate environmental impacts without hindering the design process.

Introduction: Progressive Tau deposition in neurofibrillary tangles and neuropil threads is the hallmark of tauopathies, a disorder group that includes Alzheimer’s disease. Since Tau is a microtubule-associated protein, a prevalent concept to explain the pathogenesis of tauopathies is that abnormal Tau modification contributes to dissociation from microtubules, assembly into multimeric β-sheets, proteotoxicity, neuronal dysfunction and cell loss. Tau also localizes in the cell nucleus and evidence supports an emerging function of Tau in DNA stability and epigenetic modulation.Methods: To better characterize the possible role of Tau in regulation of chromatin compaction and subsequent gene expression, we performed a bioinformatics analysis of transcriptome data obtained from Tau-depleted human neuroblastoma cells.Results: Among the transcripts deregulated in a Tau-dependent manner, we found an enrichment of target genes for the polycomb repressive complex 2. We further describe decreased cellular amounts of the core components of the polycomb repressive complex 2 and lower histone 3 trimethylation in Tau deficient cells. Among the de-repressed polycomb repressive complex 2 target gene products, IGFBP3 protein was found to be linked to increased senescence induction in Tau-deficient cells.Discussion: Our findings propose a mechanism for Tau-dependent epigenetic modulation of cell senescence, a key event in pathologic aging.

The increasing use of nanomaterials in high-tech devices has posed an exciting challenge for the scientific community to develop new, easy, high-throughput nanofabrication approaches. Here, we present an easy AFM-based nanofabrication approach based on Static Plowing Lithography, with which we are able to realize patterns of 3D nanostructures on a thin PMMA layer. By coupling a wet etching process with ultrasound exposure, we effectively removed the polymer bulges at the nanostructure’s borders, increasing the quality of the patterned 3D nanostructures, and paving the way for their integration into lab-on-a-chip devices.

Nowadays, mechanical AFM-based nanolithography has emerged as the most promising nanolithography technique, allowing the patterning of nanostructures on polymer layers with a sub-nanometer resolution. In such a stimulating context, we developed the Pulse-AFM method to obtain continuous structures with a controlled depth profile, either constant or variable, on a polymer layer. However, those nanostructures are contoured by polymer pile-ups that limit their integration into high-tech devices. Since pile-up removal is still an open challenge, AFM force–distance curve analysis was performed to characterize the stiffness of bulges, and an effective strategy to easily remove pile-ups while preserving the shape and morphology of nanostructures was then developed.

The quest for novel nanoscale materials for different applications necessitates that they are easy to obtain and have excellent physical properties and low toxicity. Moreover, considering the ongoing environmental impact of noxious chemical waste products, it is important to adopt eco-friendly approaches for nanoparticle synthesis. In this work, a natural polymer (medium molecular weight chitosan) derived from chitin was employed as a reducing agent to obtain gold nanoparticles (AuNPs) with a chitosan shell (AuNPs@CS) by a microwave oven. The chitosan is economically viable and cost-competitive in the market showing also nontoxic behavior in the environment and living organisms. The synthesized AuNPs@CS-FITC NPs were fully characterized by spectroscopic and microscopic characterization techniques. The size distribution of NPs was about 15 nm, which is a suitable dimension to use in biomedical applications due to their high tissue penetration, great circulation in blood, and optimal clearance as well as low toxicity. The prepared polymer-capped NPs were further functionalized with a fluorescent molecule, i.e., Fluorescein-5-isothiocyanate (FITC), to perform imaging in the cell. The results highlighted the goodness of the synthesis procedure, as well as the high internalization rate that resulted in an optimal fluorescence intensity. Thus, this work presents a good sustainable/green approach-mediated polymer nanocomposite for various applications in the field of diagnostic imaging.

Abstract Inhibitors of the Bromo‐ and Extra‐Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. Limited single‐agent activity has been reported in the clinical setting. Here, we have performed a pharmacological screening to identify compounds that can increase the antitumor activity of BET inhibitors in lymphomas. The germinal center B‐cell like diffuse large B‐cell lymphoma (DLBCL) cell lines OCI‐LY‐19 and WSU‐DLCL2 were exposed to 348 compounds given as single agents at two different concentrations and in combination with the BET inhibitor birabresib. The combination partners included small molecules targeting important biologic pathways such as PI3K/AKT/MAPK signaling and apoptosis, approved anticancer agents, kinase inhibitors, epigenetic compounds. The screening identified a series of compounds leading to a stronger antiproliferative activity when given in combination than as single agents: the histone deacetylase (HDAC) inhibitors panobinostat and dacinostat, the mTOR (mechanistic target of rapamycin) inhibitor everolimus, the ABL/SRC (ABL proto‐oncogene/SRC proto oncogene) inhibitor dasatinib, the AKT1/2/3 inhibitor MK‐2206, the JAK2 inhibitor TG101209. The novel finding was the benefit given by the addition of the LRRK2 inhibitor LRRK2‐IN‐1, which was validated in vitro and in vivo. Genetic silencing demonstrated that LRRK2 sustains the proliferation of lymphoma cells, a finding paired with the association between high expression levels and inferior outcome in DLBCL patients. We identified combinations that can improve the response to BET inhibitors in lymphomas, and LRRK2 as a gene essential for lymphomas and as putative novel target for this type of tumors.

Breast cancer is the most common cancer among women, with over 1 million new cases and around 400,000 deaths annually worldwide. This makes it a significant and costly global health challenge. Standard treatments like chemotherapy and radiotherapy, often used after mastectomy, show varying effectiveness based on the cancer subtype. Combining these treatments can improve outcomes, though radiotherapy faces limitations such as radiation resistance and low selectivity for malignant cells. Nanotechnologies, especially metallic nanoparticles (NPs), hold promise for enhancing radiotherapy. Gold nanoparticles (AuNPs) are particularly notable due to their high atomic number, which enhances radiation damage through the photoelectric effect. Studies shown that AuNPs can act as effective radiosensitizers, improving tumor damage during radiotherapy increasing the local radiation dose delivered. Traditional AuNPs synthesis methods involve harmful chemicals and extreme conditions, posing health risks. Green synthesis methods using plant extracts offer a safer and more environmentally friendly alternative. This study investigates the synthesis of AuNPs using Laurus nobilis leaf extract and their potential as radiosensitizers in breast carcinoma cell lines (MCF-7). These cells were exposed to varying doses of X-ray irradiation, and the study assessed cell viability, morphological changes and DNA damage. The results showed that green-synthesized AuNPs significantly enhanced the therapeutic effects of radiotherapy at lower radiation doses, indicating their potential as a valuable addition to breast cancer treatment. [ABSTRACT FROM AUTHOR]

Summary: Camidanlumab tesirine (ADCT‐301) is a CD25‐specific antibody‐drug conjugate (ADC) employing SG3199, a highly cytotoxic DNA minor groove cross‐linking pyrrolobenzodiazepine dimer. The ADC has shown early clinical antitumour activity in various cancers, including B‐ and T‐cell lymphomas. We assessed its preclinical activity as a single agent in 57 lymphoma cell lines and in combination with selected drugs in T‐cell lymphoma‐derived cell lines. Cells were exposed to increasing concentrations of the ADC or SG3199 for 96 h, followed by an MTT proliferation assay. CD25 expression was measured at cell surface and RNA levels. Experiments with PDX‐derived cell lines were used for validation studies. Camidanlumab tesirine presented more potent single agent in vitro cytotoxic activity in T‐ than B‐cell lymphomas. In vitro activity was correlated with CD25 cell surface and RNA expression. In vitro activity was correlated with CD25 cell surface and RNA expression. When camidanlumab tesirine‐containing combinations were evaluated in four T‐cell lymphoma models, the most active partners were everolimus, copanlisib, venetoclax, vorinostat, and pralatrexate, followed by bortezomib, romidepsin, bendamustine, and 5‐azacytidine. The strong camidanlumab tesirine single‐agent anti‐lymphoma activity and the in vitro synergisms with targeted agents identify potential combination partners for future clinical studies. [ABSTRACT FROM AUTHOR]

In recent years, the contamination of aquatic environments by organic chemicals, including dyes such as methylene blue (MB), Congo red, and crystal violet, has become an increasing concern, as has their treatment. In this work, titanium dioxide nanoparticles (TiO2 NPs) were studied for their photocatalytic performance by measuring the degradation of MB under UV light. TiO2 NPs were synthesized using two synthetic processes optimized in this study: a green method, namely leveraging the natural properties of Aloe vera leaf extract; and a conventional approach. The resulting NPs were thoroughly characterized using X-rays Diffraction (XRD), Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Brunauer–Emmett–Teller (BET), UV–Vis and ζ-potential analysis. The TiO2 NPs synthesized by the green method demonstrated a degradation efficiency of (50 ± 3)% after 180 min, which was significantly higher than the (16 ± 3)% achieved by NPs synthesized through the conventional route. Moreover, the reaction rate constant for the green-synthesized TiO2 NPs was found to be approximately five times greater than that of the conventionally synthesized NPs. These results open up a new scenario in the pollution removal strategy research, using resources accessible in nature to synthesize NPs with high photocatalytic activity, which could also be useful for other applications, such as hydrogen production. [ABSTRACT FROM AUTHOR]

The utilization of hydrogen (H2) as a renewable and clean energy carrier, free from the reliance on fossil fuels, represents a significant technological challenge. The use of renewable energy sources for hydrogen production, such as photocatalytic hydrogen generation from water under solar radiation, has garnered significant interest. Indeed, the storage of hydrogen presents another hurdle to the ongoing advancement of hydrogen energy. Concerning solid-state hydrogen storage, magnesium hydride (MgH2) has emerged as a promising option due to its high capacity, excellent reversibility, and cost-effectiveness. Nevertheless, its storage performance needs improvement to make it suitable for practical applications. Titanium dioxide (TiO2) has distinguished itself as the most extensively researched photocatalyst owing to its high photo-activity, good chemical and thermal stability, low toxicity, and affordability. This review highlights the application of TiO2 for hydrogen production under visible and solar light, with a particular focus both on its modification without the use of noble metals and its utilization as a catalyst to enhance the hydrogen storage performance of MgH2.

Aim: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targeting as an anti-cancer approach. BET degraders are chimeric compounds comprising of a BET inhibitor, which allows the binding to BET bromodomains, linked to a small molecule, binder for an E3 ubiquitin ligase complex, triggering BET proteins degradation via the proteasome. These degraders, called proteolysis-targeting chimeras (PROTACs), can exhibit greater target specificity compared to BET inhibitors and overcome some of their limitations, such as the upregulation of the BET proteins themselves. Here are presented data on the anti-tumor activity and the mechanism of action of the BET degrader MZ1 in diffuse large B cell lymphoma (DLBCL) of the activated B-cell like (ABC, ABC DLBCL), using a BET inhibitor as a comparison. Methods: Established lymphoma cell lines were exposed for 72 h to increasing doses of the compounds. Cell proliferation was evaluated by using an 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide (MTT) assay. Fluorescent-Activated Cell Sorter (FACS) analysis was performed to measure apoptotic activation and RNA sequencing (RNA-Seq) to study the transcriptional changes induced by the compounds. Results: MZ1, and not its negative control epimer cisMZ1, was very active with a median half maximal inhibitory concentration (IC50) of 49 nmol/L. MZ1 was more in vitro active than the BET inhibitor birabresib (OTX015). Importantly, MZ1 induced cell death in all the ABC DLBCL cell lines, while the BET inhibitor was cytotoxic only in a fraction of them. BET degrader and inhibitor shared partially similar changes at transcriptome level but the MZ1 effect was stronger and overlapped with that caused cyclin-dependent kinase 9 (CDK9) inhibition. Conclusions: The BET degrader MZ1 had strong cytotoxic activity in all the ABC DLBCL cell lines that were tested, and, at least in vitro, it elicited more profound effects than BET inhibitors, and encourages further investigations.